Health Rounds: Experimental drug delays heart valve disease progression, and potentially surgery
An experimental drug originally developed by Sanofi (SASY.PA), opens new tab that is now being advanced by the Mayo Clinic significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, researchers reported.
Čítajte ďalej na https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-experimental-drug-delays-heart-valve-disease-progression-2025-02-27/